Simulations Plus, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Shawn O'Connor
- Full Time Employees
- 243
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- 42505 Tenth Street West Lancaster CA United States of America 93534-7059
- IPO Date
- Jun 18, 1997
- CIK
- 0001023459
- Website
- simulations-plus.com
- Similar Companies
- Business
- Simulations Plus, Inc. (Nasdaq: SLP) develops and markets modeling and simulation software, along with related consulting services, for drug discovery, development research, and regulatory submissions in the pharmaceutical, biotechnology, agrochemical, cosmetics, and food industries worldwide. The company operates through Software and Services segments and offers core products including GastroPlus for physiologically based biopharmaceutics (PBPK) modeling of absorption, pharmacokinetics, and pharmacodynamics in humans and animals; ADMET Predictor, a machine learning platform for absorption, distribution, metabolism, excretion, and toxicity property prediction, data analysis, metabolism forecasting, and AI-driven drug design; DDDPlus and MembranePlus for in vitro dissolution, permeability, and hepatocyte modeling; MonolixSuite for population pharmacokinetic/pharmacodynamic (PK/PD) analyses, clinical trial simulations, and regulatory submissions; quantitative systems pharmacology/toxicology platforms such as DILIsym, RENAsym, NAFLDsym, ILDsym, IPFsym, OBESITYsym, and MITOsym for mechanistic predictions of drug-induced organ injuries and disease efficacy; MedChem Designer for molecular sketching and ADMET predictions; Thales for end-to-end QSP modeling and population optimization; Panorama for key opinion leader analytics and medical communications; and Pro-ficiency for AI-driven clinical trial simulations, performance management, adaptive learning, and insights. Simulations Plus provides clinical pharmacology consulting encompassing population PK/PD modeling, exposure-response analyses, noncompartmental analysis, pharmacometrics with Monolix and NONMEM, data programming, technical writing for regulatory filings, and early drug discovery support leveraging AI/ML and PBPK integration. Founded in 1996 and headquartered in Research Triangle Park, North Carolina, the company serves major pharmaceutical and biotechnology firms, chemical manufacturers, academic institutions, and regulatory agencies across the United States, Europe, Asia-Pacific, and other regions. In June 2024, Simulations Plus completed its largest acquisition to date with the $100 million cash purchase of Pro-ficiency Holdings, Inc. and subsidiaries from QHP Capital, doubling its total addressable market to $8 billion by integrating AI-powered clinical trial operations, training simulations, analytics, and medical communications capabilities; the deal, funded from existing cash reserves, proved accretive to fiscal 2025 earnings and expanded offerings from preclinical protocols through product commercialization. Subsequently, in August 2024, the company restructured into new business units—Adaptive Learning & Insights and Medical Communications—to optimize post-acquisition operations and enhance client engagement; in October 2025, its board adopted a revised Code of Conduct incorporating AI usage best practices while maintaining core governance principles.
Robbins LLP Reminds SLP Stockholders of its Investigation into Simulation Plus, Inc.; Contact the Firm for Information
Simulations Plus (SLP) Securities Investigation: Johnson Fistel Reviews Revenue Guidance Cut, $77.2M Impairment Charge, and Auditor Dispute
RBC initiates on Sylvania Platinum with 175p target, calling it cheap versus quality
Johnson Fistel Investigates Simulations Plus, Inc. (SLP) After Revenue Guidance Cut, Impairment Charge, and Auditor Dispute
Simulation Plus, Inc. Securities Fraud Investigation – Robbins LLP is Investigating Investor Losses in SLP Due to Possible Violations of Securities Laws
Simulations Plus, Inc. (SLP) Investigation: Johnson Fistel Investigates Investor Losses Following Revenue Guidance Cut, Impairment Charge, and Auditor Dispute
SLP Shareholder Alert: Robbins LLP Reminds Simulation Plus, Inc. Stockholders that it is Investigating the Company's Officers and Directors to Determine if They Violated Securities Laws and Breached Fiduciary Duties to Shareholders
SLP Shareholder Alert: Robbins LLP Reminds Simulation Plus, Inc. Stockholders that it is Investigating the Company's Officers and Directors to Determine if They Violated Securities Laws and Breached F
SLP Shareholder Alert: Robbins LLP Reminds Simulation Plus, Inc. Stockholders that it is Investigating the Company's Officers and Directors to Determine if They Violated Securities Laws and Breached Fiduciary Duties to Shareholders
Simulations Plus, Inc. (SLP) Securities Fraud Investigation: Johnson Fistel Investigates Investor Losses Following Revenue Outlook Revision, Impairment Charge, and Auditor Dispute
Robbins LLP is Investigating Allegations that the Officers and Directors of Simulations Plus, Inc. (SLP) Violated Securities Laws and Breached Fiduciary Duties to Shareholders
Simulations Plus, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses
Simulations Plus to Participate in the 23rd Annual Craig-Hallum Institutional Investor Conference
Simulations Plus Collaborates With Nvidia During AI Drug Modeling Push
Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows
Cadence Q1 Earnings Top Estimates, 2026 Revenue Outlook Raised
Simulations Plus, Inc. (NASDAQ:SLP) Receives Consensus Rating of “Hold” from Brokerages
Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products
Simulations Plus Expands Global Access to Model-Informed Drug Development Training Through Its 2026 Spring School
Simulations Plus: Better Quarter, Same Doubts